CFM
EBS icon

Catalyst Funds Management’s Emergent Biosolutions EBS Stock Holding History

Catalyst Funds Management’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-31,741
Closed -$154K – 515
2025
Q1 		$154K Buy
+31,741
New +$263K 0.04% 365
2024
Q4 		– Sell
-10,400
Closed -$86.8K – 605
2024
Q3 		$86.8K Hold
10,400
– – 0.02% 545
2024
Q2 		$70.9K Buy
+10,400
New +$44.8K 0.02% 353

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OHA
Oak Hill Advisors New York $878M AUM 106.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Catalyst Funds Management's EBS Position: Q2 2025 in Review

Catalyst Funds Management sold out of Emergent Biosolutions (EBS) in Q2 2025, closing a stake of 31,741 shares — an estimated $154K sold.

Catalyst Funds Management first reported a position in EBS in Q2 2024 and held it in 3 quarters. The position peaked at $154K in Q1 2025. 161 funds tracked by Wall St. Rank hold EBS as of Q2 2025.

  • Catalyst Funds Management reported no remaining Emergent Biosolutions position as of Q2 2025 after selling out during the quarter.
  • Catalyst Funds Management sold 31,741 Emergent Biosolutions shares in Q2 2025, an estimated $154K.
  • Catalyst Funds Management first reported a position in Emergent Biosolutions in Q2 2024 and held it in 3 quarters.
  • Catalyst Funds Management's Emergent Biosolutions position peaked at $154K in Q1 2025.
  • 161 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2025.

Based on Catalyst Funds Management's 13F filing for Q2 2025, filed 12 Aug 2025.